The Functional Medicine Approach to Elevated Liver Enzymes: From Conventional Work-Up to Root-Cause Resolution
By Yoon Hang Kim, MD, MPH
Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician
Medical Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. It is not intended to replace a consultation with a qualified healthcare professional. Always discuss any changes to your health regimen with your personal physician or provider.
Introduction
Elevated liver enzymes — particularly alanine aminotransferase (ALT) and aspartate aminotransferase (AST) — are among the most common incidental laboratory findings in adult medicine. They appear on routine panels, pre-operative screens, and insurance physicals, and they frequently catch both clinicians and clients off guard. In most cases the elevations are mild (less than three times the upper limit of normal) and the individual is asymptomatic, yet persistently abnormal values always warrant a systematic evaluation.
The conventional approach — confirm, characterize the pattern, and screen for common etiologies — remains the indispensable starting point.[1] Where functional medicine adds value is in the second layer: once red-flag diagnoses have been excluded, a root-cause framework can identify the metabolic, dietary, toxic, and gut-liver drivers that standard algorithms often underexplore. This article outlines both layers and reviews the evidence for silymarin (milk thistle extract) as an adjunctive hepatoprotective agent.
Part 1: The Conventional Work-Up
When you first encounter mildly elevated transaminases, the priorities are to confirm persistence, define the biochemical pattern, and assess hepatic synthetic function.[2]
Confirm and Characterize
Repeat the full liver panel: AST, ALT, alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total and direct bilirubin, albumin, and prothrombin time/INR. This step distinguishes a hepatocellular pattern (AST/ALT predominant) from a cholestatic pattern (ALP/GGT predominant) and checks for impaired synthetic function — a signal of more advanced disease.[2]
Targeted History
A detailed history is critical: alcohol intake (quantified with a tool such as the AUDIT-C), complete medication and supplement inventory (prescription, OTC, herbal, and botanical), occupational or environmental toxin exposures, recent strenuous exercise or muscle injury, transfusion history, sexual and intravenous drug risk factors, travel history, and family history of liver disease.[3]
Metabolic Profile
Metabolic dysfunction-associated steatotic liver disease (MASLD) — formerly termed NAFLD — is now the most common cause of chronically elevated transaminases in adults.[4] Screening for metabolic syndrome is therefore essential: BMI and waist circumference, blood pressure, fasting glucose or HbA1c, and a full lipid panel.
Baseline Laboratory Evaluation
Beyond the liver panel, initial labs should include a CBC, comprehensive metabolic panel, iron studies (ferritin and transferrin saturation), TSH, and creatine kinase (CK) to exclude a muscular source of AST elevation. Additional studies such as LDH and hemolysis labs are ordered when clinically indicated.[2]
Hepatitis and Autoimmune Screening
Viral hepatitis serologies (HBsAg, anti-HBc, anti-HCV) are part of the standard work-up. When autoimmune hepatitis is in the differential, add ANA, anti-smooth muscle antibody, and quantitative immunoglobulin G.[2]
Imaging
Abdominal ultrasound is the appropriate first-line imaging study, with good sensitivity and specificity for moderate-to-severe hepatic steatosis. It also screens for biliary obstruction, focal hepatic lesions, and signs of cirrhosis.[1]
Core Differential Diagnosis
The differential for hepatocellular enzyme elevations (AST/ALT predominant) includes several common and several less common but important entities.[4]
Common Etiologies
MASLD/NAFLD is by far the most prevalent cause, associated with central obesity, insulin resistance, and dyslipidemia. Early in the disease course, the AST-to-ALT ratio is typically less than 1 and synthetic function is preserved.[1]
Alcohol-related liver disease classically presents with an AST-to-ALT ratio greater than 2, often accompanied by macrocytosis and a history consistent with heavy or sustained alcohol use.[5]
Drug-induced liver injury (DILI) is a substantial contributor to abnormal liver function tests. Common offenders include antimicrobials, antiepileptics, statins, NSAIDs, psychotropics, and many botanical and herbal products.[3]
Chronic viral hepatitis B and C should always be considered if serologies have not been obtained or if risk factors are present.[2]
Autoimmune hepatitis typically presents with higher ALT values, hypergammaglobulinemia, and positive autoantibodies.[2]
Less Common but Important
Hereditary hemochromatosis (elevated ferritin and transferrin saturation), Wilson disease (younger clients, low ceruloplasmin, elevated 24-hour urine copper), and alpha-1 antitrypsin deficiency (family history, concurrent pulmonary disease) should be considered when initial screening is unrevealing. Non-hepatic causes of AST elevation — including muscle disorders (elevated CK), thyroid dysfunction, hemolysis, and cardiac injury — must also be excluded.[2]
Escalation
If transaminases remain persistently elevated after an initial work-up, or if there is clinical or laboratory evidence of fibrosis, consider transient elastography (FibroScan) or referral for liver biopsy.[1]
Pattern-Oriented Summary
Part 2: The Functional Medicine Assessment
Once urgent and major conventional etiologies have been ruled out, a functional medicine framework refines the root-cause analysis and expands the treatment plan across several interconnected domains.
Metabolic and Mitochondrial Drivers
A comprehensive evaluation of insulin resistance, visceral adiposity, dyslipidemia, uric acid, obstructive sleep apnea, and sarcopenia addresses the core metabolic drivers of MASLD and chronic transaminase elevation.[4]
Dietary and Lifestyle Load
Ultra-processed foods, excess fructose, trans fats, a disproportionate omega-6-to-omega-3 ratio, and even so-called "moderate" alcohol use in susceptible individuals can all contribute to hepatic inflammation. Circadian disruption, poor sleep quality, and sedentary behavior compound the metabolic burden.
Toxic Burden
Occupational solvent exposure, pesticides, heavy metals, and mold-derived volatile organic compounds contribute to hepatic stress. The cumulative pharmacologic and supplement load itself can participate in DILI, making a thorough inventory essential.[3]
The Gut–Liver Axis
Small intestinal bacterial overgrowth (SIBO), dysbiosis, increased intestinal permeability, and MASLD-associated microbiome changes with resulting endotoxemia are recognized contributors to hepatic inflammation.[4] Addressing the gut–liver axis is a core tenet of functional hepatology.
Immune and Inflammatory Milieu
Low-grade autoimmunity, chronic infections, the adipocytokine profile, and systemic inflammatory markers (hs-CRP and others as clinically relevant) round out the functional assessment.
Functional Interventions
Nutritional optimization. A low-glycemic, anti-inflammatory dietary pattern — Mediterranean or modified — with caloric control for weight loss where indicated, fructose limitation, adequate protein and choline, and higher phytonutrient intake forms the nutritional foundation. Coffee, notably, appears broadly hepatoprotective in observational data and can be encouraged when tolerated.
Movement. Daily moderate cardiovascular exercise combined with resistance training improves insulin sensitivity and reduces hepatic fat. Even modest weight loss (5–10% of body weight) yields measurable improvements in transaminase levels and hepatic steatosis on imaging.[1]
Toxin minimization. Rational deprescribing, avoidance of hepatotoxic botanicals, personal and occupational toxin mitigation, and targeted nutritional support for biotransformation pathways are integral to reducing hepatic burden.
Gut support. Treatment of SIBO or dysbiosis when present, increased fermentable fiber intake (if tolerated), and consideration of strain-specific probiotics with emerging data in MASLD support the gut–liver axis.
Micronutrient repletion. Optimizing vitamin D, magnesium, omega-3 fatty acids, and other deficiencies that commonly track with metabolic and inflammatory burden provides biologically plausible — if largely indirect — hepatic support.
Silymarin (Milk Thistle): Evidence and Practical Use
Silymarin — the standardized extract of milk thistle (Silybum marianum) — has a long history in traditional hepatology and a growing, though still heterogeneous, evidence base in modern clinical research.
Mechanisms
Preclinical models demonstrate antioxidative, anti-inflammatory, and antifibrotic effects. Silymarin modulates hepatocyte membrane permeability, scavenges reactive oxygen species, and inhibits NF-κB-mediated inflammatory signaling.[6]
Evidence in MASLD/NAFLD
A 2024 meta-analysis of nine clinical trials in MASLD found that silymarin significantly reduced ALT (mean difference approximately −17 IU/L) and AST (approximately −13 IU/L), lowered triglycerides, and modestly improved HDL. One included study demonstrated improvement in fibrosis scores.[7]
A 2023 systematic review of 29 randomized controlled trials across multiple conditions reported that approximately two-thirds (65.5%) of studies showed reduced liver enzyme levels with silymarin, 20.7% showed no significant change, and 13.8% showed increases — with the most consistent benefit observed in MASLD.[8]
An observational study of 190 clients with drug-induced elevated liver enzymes reported significant reductions in all documented laboratory parameters (p < 0.001) and marked improvement in liver-related symptoms and quality of life within two to four months, with no observed adverse drug reactions.[9]
Evidence in Other Chronic Liver Diseases
In alcoholic liver disease, older meta-analytic data suggest that silymarin may reduce liver-related mortality and improve histology and prothrombin time, although overall mortality benefit was not statistically robust and the available trials were underpowered.[5]
In chronic hepatitis C, high-dose silymarin did not significantly change viral loads or quality-of-life measures in a major trial. Silymarin should not be considered antiviral therapy.[10]
Safety, Dosing, and Formulation
Silymarin has an excellent safety record across clinical trials and observational series, with rare reports limited to mild gastrointestinal upset or allergic rash.[9]
Typical trial doses range from 140 to 420 mg per day of standardized silymarin, often in divided doses. Many MASLD studies employ the 420 mg/day dosage.[7]
Bioavailability remains a significant limitation of standard silymarin preparations. Complexed formulations — for example, those utilizing phosphatidylcholine — can substantially improve absorption and are an important consideration when selecting a product.[10]
Drug interactions appear limited in most clinical contexts. Prudent monitoring is warranted in polypharmacy settings, and P-glycoprotein and CYP-mediated interactions should be considered in complex oncology or transplant regimens.[10]
Putting It Together: A Pragmatic Clinical Algorithm
For persistent, non-acute liver enzyme elevations, the following stepwise approach integrates conventional and functional medicine principles:
Step 1 — Confirm and characterize. Repeat full liver function tests, assess the biochemical pattern and degree of elevation, check synthetic function and CK, and obtain abdominal ultrasound.[1]
Step 2 — Rule out red-flag etiologies. Obtain viral hepatitis serologies, quantify alcohol exposure and screen for DILI, check autoimmune markers, iron studies, and thyroid function. Escalate to elastography or biopsy when indicated.[3]
Step 3 — Quantify metabolic and lifestyle drivers. Assess metabolic syndrome parameters, dietary and sleep patterns, physical activity level, gut health, and environmental and pharmacologic toxin burden.
Step 4 — Implement the core lifestyle and metabolic protocol. Weight reduction where appropriate, dietary overhaul (low-glycemic, anti-inflammatory), structured exercise, alcohol restriction or abstinence, and targeted gut–liver support.
Step 5 — Consider silymarin as an adjunct. A standardized product at 140–420 mg/day — preferably a bioavailability-enhanced formulation — for 8–12 weeks, with repeat labs at the 8- to 12-week mark and again at 6 months.[7]
Step 6 — Re-evaluate. If enzymes normalize with metabolic and supportive care, maintain the protocol and de-escalate as appropriate. If values remain abnormal or worsen, revisit the differential, look again for occult DILI, autoimmune, or genetic disease, and consider referral for advanced imaging or liver biopsy.[1]
Clinical Example
Consider a middle-aged client with a BMI of 32, mild AST/ALT elevation, ultrasound-confirmed hepatic steatosis, and a negative viral and autoimmune work-up. After intensively addressing metabolic syndrome and counseling on modest alcohol use, silymarin is layered in (for example, 420 mg/day of a well-absorbed formulation) while tracking liver function tests and fibrosis markers. If labs and fibrosis scores improve over 6 to 12 months, silymarin may be continued intermittently as part of a longer-term hepatic support plan — recognizing that it is adjunctive rather than curative.[8]
Conclusion
Persistently elevated liver enzymes are a signal, not a diagnosis. The functional medicine approach layers a root-cause investigation — metabolic, toxic, gut-liver, and lifestyle domains — onto the essential conventional work-up and differential. Silymarin occupies a reasonable adjunctive role, particularly in MASLD, supported by a favorable safety profile and meta-analytic evidence of modest transaminase reduction. The strongest therapeutic lever, however, remains the comprehensive metabolic and lifestyle protocol: dietary optimization, movement, toxin reduction, and gut support. That is where the most durable clinical gains are made.
References
[1] Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342(17):1266–1271. Reviewed in: AAFP, "Evaluation of Mildly Elevated Liver Transaminase Levels," Am Fam Physician. 2006;73(11):1961–1968.
[2] DrOracle. Differential diagnoses for elevated liver enzymes: a clinical decision-support review. Available at: droracle.ai.
[3] Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112(1):18–35. doi:10.1038/ajg.2016.517. PMID: 27995906.
[4] Chronic liver disease and management with silymarin: an introductory review. PMC. 2024. PMC10852028.
[5] Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035–2063. PMID: 11735632.
[6] Gillessen A, Schmidt HHJ. Silymarin as supportive treatment in liver diseases: a narrative review. Adv Ther. 2020;37(4):1279–1301. doi:10.1007/s12325-020-01251-y. PMID: 32065376.
[7] Malik A, Malik M, Qureshi S. Effects of silymarin use on liver enzymes and metabolic factors in MASLD: a systematic review and meta-analysis. Can Liver J. 2024;7(1):56–66. PMID: 38505782.
[8] Calderon Martinez E, Herrera D, Mogan S, et al. Impact of silymarin supplements on liver enzyme levels: a systematic review. Cureus. 2023;15(10):e47608. PMID: 38021897.
[9] Gillessen A, Herrmann WA, Kemper M, et al. Effect of silymarin on liver health and quality of life: results of a non-interventional study. MMW Fortschr Med. 2014;156 Suppl 4:120–126. PMID: 26153591.
[10] Ferenci P. Silymarin in the treatment of liver diseases: What is the clinical evidence? Clin Liver Dis (Hoboken). 2016;7(1):8–10. PMC6490246.
About Dr. Kim
Dr. Yoon Hang "John" Kim is board-certified in Preventive Medicine with 20+ years of experience. Fellowship-trained at the University of Arizona Andrew Weil Center for Integrative Medicine (Osher Fellow). Certified in Medical Acupuncture (UCLA), Integrative & Holistic Medicine, and Functional Medicine. Specializes in LDN, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, CFS/ME, MCAS, and mold toxicity. Author of 3 books and 20+ peer-reviewed articles. Professional site: www.yoonhangkim.com | Clinical practice: www.directintegrativecare.com
